|
Polycystic Ovary Syndrome
|
0.270 |
GeneticVariation
|
disease |
BEFREE |
Identification of a functional polymorphism of the human type 5 17beta-hydroxysteroid dehydrogenase gene associated with polycystic ovary syndrome.
|
16263811 |
2006 |
|
Polycystic Ovary Syndrome
|
0.270 |
GeneticVariation
|
disease |
BEFREE |
To evaluate the association of an activating single-nucleotide polymorphism (SNP) at position -71 of the promoter of 17beta-hydroxysteroid dehydrogenase type 5 gene (-71A/G HSD17B5 SNP) and polycystic ovary syndrome (PCOS) in a well characterized cohort of caucasian PCOS women with biochemical hyperandrogenemia.
|
18692800 |
2009 |
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The 17HSD type 2 gene (HSD17B2) was screened for mutations with Single Stranded Conformation Polymorphism (SSCP)-DNA sequencing in 59 sporadic breast cancer cases, 19 hereditary breast cancer cases and seven breast cancer cell lines.
|
17260097 |
2007 |
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We tested the hypothesis that polymorphisms in cytochrome P450c17alpha (CYP17), aromatase (CYP19), 17beta-hydroxysteroid dehydrogenase type I (17beta-HSD1) and sex hormone-binding globulin (SHBG) genes may modify the association between isoflavone intake and breast cancer risk.
|
20432167 |
2010 |
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To determine whether associations between estrogen pathway-related single nucleotide polymorphisms (SNPs) and breast cancer risk differ by molecular subtype, we evaluated associations between SNPs in cytochrome P450 family 19 subfamily A polypeptide 1 (CYP19A1), estrogen receptor (ESR1), 3-beta hydroxysteroid dehydrogenase type I (HSD3B1), 17-beta hydroxysteroid dehydrogenase type II (HSD17B2), progesterone receptor (PGR), and sex hormone-binding globulin (SHBG) and breast cancer risk in a case-control study in North Carolina.
|
25421376 |
2015 |
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer.
|
19460435 |
2009 |
|
Endometriosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Involvement of 17β-hydroxysteroid dehydrogenase type gene 1 937 A>G polymorphism in infertility in Polish Caucasian women with endometriosis.
|
28405865 |
2017 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To determine whether associations between estrogen pathway-related single nucleotide polymorphisms (SNPs) and breast cancer risk differ by molecular subtype, we evaluated associations between SNPs in cytochrome P450 family 19 subfamily A polypeptide 1 (CYP19A1), estrogen receptor (ESR1), 3-beta hydroxysteroid dehydrogenase type I (HSD3B1), 17-beta hydroxysteroid dehydrogenase type II (HSD17B2), progesterone receptor (PGR), and sex hormone-binding globulin (SHBG) and breast cancer risk in a case-control study in North Carolina.
|
25421376 |
2015 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The 17HSD type 2 gene (HSD17B2) was screened for mutations with Single Stranded Conformation Polymorphism (SSCP)-DNA sequencing in 59 sporadic breast cancer cases, 19 hereditary breast cancer cases and seven breast cancer cell lines.
|
17260097 |
2007 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer.
|
19460435 |
2009 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We tested the hypothesis that polymorphisms in cytochrome P450c17alpha (CYP17), aromatase (CYP19), 17beta-hydroxysteroid dehydrogenase type I (17beta-HSD1) and sex hormone-binding globulin (SHBG) genes may modify the association between isoflavone intake and breast cancer risk.
|
20432167 |
2010 |
|
Neoplasms
|
0.070 |
GeneticVariation
|
group |
BEFREE |
ESR1 (9.1-fold; P < 0.001) and HSD17B7 (3.5-fold; P < 0.001) were upregulated in ER(+) tumors compared with normal tissues, whereas STS (0.34-fold; P < 0.001) and HSD17B5 (0.23-fold; P < 0.001) were downregulated.
|
20215536 |
2010 |
|
Malignant neoplasm of prostate
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
We performed genotyping of SNP in the HSD17B genes of 44 Japanese patients with newly diagnosed prostate cancer.
|
15733111 |
2005 |
|
Prostate carcinoma
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
We performed genotyping of SNP in the HSD17B genes of 44 Japanese patients with newly diagnosed prostate cancer.
|
15733111 |
2005 |
|
Male Pseudohermaphroditism
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
We studied the molecular genetics of a large isolated inbred Turkish kindred with MPH due to either 5 alpha-reductase-2 (SRD5A2) or 17 beta-hydroxysteroid dehydrogenase-3 (17 beta HSD3) gene defects.
|
9467575 |
1998 |
|
Mammary Neoplasms
|
0.040 |
GeneticVariation
|
group |
BEFREE |
The question whether 17HSD type 1 or type 2 is of greatest importance in breast tumour development is still not clear.
|
16954436 |
2006 |
|
46, XY Disorders of Sex Development
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Screening for mutations in 17β-hydroxysteroid dehydrogenase and androgen receptor in women presenting with partially virilised 46,XY disorders of sex development.
|
25740850 |
2015 |
|
46, XY Disorders of Sex Development
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Deficiency of 17β-hydroxysteroid dehydrogenase type3 (17β-HSD3) isoenzyme which catalyzes the synthesis of testosterone from Δ4-androstenedione, is the cause of 46, XY disorders of sex development (DSD).
|
25064799 |
2015 |
|
46, XY Disorders of Sex Development
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Biochemical analyses and molecular modeling explain the functional loss of 17β-hydroxysteroid dehydrogenase 3 mutant G133R in three Tunisian patients with 46, XY Disorders of Sex Development.
|
26545797 |
2016 |
|
pseudohermaphrodite (non-specific)
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The identification of 5 alpha-reductase-2 and 17 beta-hydroxysteroid dehydrogenase-3 gene defects in male pseudohermaphrodites from a Turkish kindred.
|
9467575 |
1998 |
|
Carcinoma, Ovarian Epithelial
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer.
|
19460435 |
2009 |
|
Malignant neoplasm of stomach
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Therefore, using reverse transcription-quantitative polymerase chain reaction analysis, the mRNA expression of genes encoding steroidogenic enzymes, including steroid sulfatase (STS), hydroxy-delta-5-steroid dehydrogenase 3 beta- and steroid delta-isomerase 1 (HSD3B1), 17β-hydroxysteroid dehydrogenase type 7 and aromatase (CYP19A1), was investigated in primary tumoral and adjacent healthy gastric mucosa from 60 patients with GC.
|
28521442 |
2017 |
|
Androgen-Insensitivity Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Gonadotropin-stimulated serum testosterone/androstenedione ratios in 17betaHSD3-deficient patients were discriminative in all cases and did not overlap with ratios in normal controls or with ratios in AIS patients.
|
10599740 |
1999 |
|
Thymoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Intratumoral E(2) concentrations were inversely correlated with EST, positively correlated with STS or 17beta-HSD type 1, and significantly higher in lower-grade or early-stage thymoma.
|
16166425 |
2005 |
|
Hyperandrogenism
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Our objective was to investigate the role of a potentially activating 17beta-HSD5 gene (HSD17B5) variant in hyperandrogenism.
|
16263811 |
2006 |